npj Vaccines (Jan 2022)
Passive transfer of Ad26.COV2.S-elicited IgG from humans attenuates SARS-CoV-2 disease in hamsters
- Lisa H. Tostanoski,
- Abishek Chandrashekar,
- Shivani Patel,
- Jingyou Yu,
- Catherine Jacob-Dolan,
- Aiquan Chang,
- Olivia C. Powers,
- Daniel Sellers,
- Sarah Gardner,
- Julia Barrett,
- Owen Sanborn,
- Kathryn E. Stephenson,
- Jessica L. Ansel,
- Kate Jaegle,
- Michael S. Seaman,
- Maciel Porto,
- Megan Lok,
- Brittany Spence,
- Kathleen Cayer,
- Danielle Nase,
- Shaikim Holman,
- Heath Bradette,
- Swagata Kar,
- Hanne Andersen,
- Mark G. Lewis,
- Freek Cox,
- Jeroen T. B. M. Tolboom,
- Anne Marit de Groot,
- Dirk Heerwegh,
- Mathieu Le Gars,
- Jerald Sadoff,
- Frank Wegmann,
- Roland C. Zahn,
- Hanneke Schuitemaker,
- Dan H. Barouch
Affiliations
- Lisa H. Tostanoski
- Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School
- Abishek Chandrashekar
- Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School
- Shivani Patel
- Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School
- Jingyou Yu
- Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School
- Catherine Jacob-Dolan
- Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School
- Aiquan Chang
- Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School
- Olivia C. Powers
- Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School
- Daniel Sellers
- Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School
- Sarah Gardner
- Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School
- Julia Barrett
- Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School
- Owen Sanborn
- Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School
- Kathryn E. Stephenson
- Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School
- Jessica L. Ansel
- Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School
- Kate Jaegle
- Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School
- Michael S. Seaman
- Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School
- Maciel Porto
- BIOQUAL, Inc.
- Megan Lok
- BIOQUAL, Inc.
- Brittany Spence
- BIOQUAL, Inc.
- Kathleen Cayer
- BIOQUAL, Inc.
- Danielle Nase
- BIOQUAL, Inc.
- Shaikim Holman
- BIOQUAL, Inc.
- Heath Bradette
- BIOQUAL, Inc.
- Swagata Kar
- BIOQUAL, Inc.
- Hanne Andersen
- BIOQUAL, Inc.
- Mark G. Lewis
- BIOQUAL, Inc.
- Freek Cox
- Janssen Vaccines & Prevention
- Jeroen T. B. M. Tolboom
- Janssen Vaccines & Prevention
- Anne Marit de Groot
- Janssen Vaccines & Prevention
- Dirk Heerwegh
- Janssen Research & Development
- Mathieu Le Gars
- Janssen Vaccines & Prevention
- Jerald Sadoff
- Janssen Vaccines & Prevention
- Frank Wegmann
- Janssen Vaccines & Prevention
- Roland C. Zahn
- Janssen Vaccines & Prevention
- Hanneke Schuitemaker
- Janssen Vaccines & Prevention
- Dan H. Barouch
- Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School
- DOI
- https://doi.org/10.1038/s41541-021-00427-z
- Journal volume & issue
-
Vol. 7,
no. 1
pp. 1 – 6
Abstract
Abstract SARS-CoV-2 Spike-specific binding and neutralizing antibodies, elicited either by natural infection or vaccination, have emerged as potential correlates of protection. An important question, however, is whether vaccine-elicited antibodies in humans provide direct, functional protection from SARS-CoV-2 infection and disease. In this study, we explored directly the protective efficacy of human antibodies elicited by Ad26.COV2.S vaccination by adoptive transfer studies. IgG from plasma of Ad26.COV2.S vaccinated individuals was purified and transferred into naïve golden Syrian hamster recipients, followed by intra-nasal challenge of the hamsters with SARS-CoV-2. IgG purified from Ad26.COV2.S-vaccinated individuals provided dose-dependent protection in the recipient hamsters from weight loss following challenge. In contrast, IgG purified from placebo recipients provided no protection in this adoptive transfer model. Attenuation of weight loss correlated with binding and neutralizing antibody titers of the passively transferred IgG. This study suggests that Ad26.COV2.S-elicited antibodies in humans are mechanistically involved in protection against SARS-CoV-2.
